Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation.

dc.contributor.authorHurtado-Guerrero, Isaac
dc.contributor.authorHernaez, Bruno
dc.contributor.authorPinto-Medel, Maria J
dc.contributor.authorCalonge, Esther
dc.contributor.authorRodriguez-Bada, Jose L
dc.contributor.authorUrbaneja, Patricia
dc.contributor.authorAlonso, Ana
dc.contributor.authorMena-Vazquez, Natalia
dc.contributor.authorAliaga, Pablo
dc.contributor.authorIssazadeh-Navikas, Shohreh
dc.contributor.authorPavia, Jose
dc.contributor.authorLeyva, Laura
dc.contributor.authorAlcami, Jose
dc.contributor.authorAlcami, Antonio
dc.contributor.authorFernandez, Oscar
dc.contributor.authorOliver-Martos, Begoña
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderEuropean Regional Development Fund (ERDF) “A way to build Europe”
dc.contributor.funderTechnological Development Project in health
dc.contributor.funderEstancias formativas de investigación, Junta de Andalucía
dc.contributor.funderRed Temática de Investigación Cooperativa: Red Española de Esclerosis Multiple REEM
dc.date.accessioned2025-01-07T14:06:55Z
dc.date.available2025-01-07T14:06:55Z
dc.date.issued2020-03-31
dc.description.abstractSoluble receptors of cytokines are able to modify cytokine activities and therefore the immune system, and some have intrinsic biological activities without mediation from their cytokines. The soluble interferon beta (IFN-ß) receptor is generated through alternative splicing of IFNAR2 and has both agonist and antagonist properties for IFN-ß, but its role is unknown. We previously demonstrated that a recombinant human soluble IFN-ß receptor showed intrinsic therapeutic efficacy in a mouse model of multiple sclerosis. Here we evaluate the potential biological activities of recombinant sIFNAR2 without the mediation of IFN-ß in human cells. Recombinant sIFNAR2 down-regulated the production of IL-17 and IFN-ɣ and reduced the cell proliferation rate. Moreover, it showed a strong antiviral activity, fully protecting the cell monolayer after being infected by the virus. Specific inhibitors completely abrogated the antiviral activity of IFN-ß, but not that of the recombinant sIFNAR2, and there was no activation of the JAK-STAT signaling pathway. Consequently, r-sIFNAR2 exerts immunomodulatory, antiproliferative and antiviral activities without IFN-ß mediation, and could be a promising treatment against viral infections and immune-mediated diseases.
dc.description.sponsorshipThis research was funded by grants from the Instituto de Salud Carlos III and co-funded by the European Regional Development Fund (ERDF) “A way to build Europe” research project PI13/00927 and Technological Development Project in health DTS/1800045 to B. Oliver-Martos. Also, this work was partially supported by Instituto de Salud Carlos III and co-funded by European Regional Development Fund (ERDF) “A way to build Europe” (projects RD12/0017/0015 and RD16CIII/0002/0001). EMBO Short-Term Fellowships (7902) and Estancias formativas de investigación, Junta de Andalucía (EF-0169-2018) to I. Hurtado. JL Rodriguez-Bada is supported by grants from Red Temática de Investigación Cooperativa: Red Española de Esclerosis Multiple REEM (RD16/0015/0010).
dc.description.versionSi
dc.identifier.citationHurtado-Guerrero I, Hernáez B, Pinto-Medel MJ, Calonge E, Rodriguez-Bada JL, Urbaneja P, et al. Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation. J Clin Med. 2020 Mar 31;9(4):959
dc.identifier.doi10.3390/jcm9040959
dc.identifier.issn2077-0383
dc.identifier.pmcPMC7230527
dc.identifier.pmid32244308
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7230527/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2077-0383/9/4/959/pdf?version=1586395777
dc.identifier.urihttps://hdl.handle.net/10668/26145
dc.issue.number4
dc.journal.titleJournal of clinical medicine
dc.journal.titleabbreviationJ Clin Med
dc.language.isoen
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.page.number20
dc.provenanceRealizada la curación de contenido 10/03/2025
dc.publisherMDPI
dc.pubmedtypeJournal Article
dc.relation.projectIDPI13/00927
dc.relation.projectIDDTS/1800045
dc.relation.projectIDRD12/0017/0015
dc.relation.projectIDRD16CIII/0002/0001
dc.relation.projectIDEF-0169-2018
dc.relation.projectIDRD16/0015/0010
dc.relation.publisherversionhttps://www.mdpi.com/resolver?pii=jcm9040959
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectIFNAR
dc.subjectImmunology
dc.subjectInterferon
dc.subjectSoluble receptors
dc.subject.decsAntivirales
dc.subject.decsNegociación
dc.subject.decsCitocinas
dc.subject.decsSistema inmunológico
dc.subject.decsEmpalme alternativo
dc.subject.decsVirosis
dc.subject.decsProliferación celular
dc.subject.meshVirus Diseases
dc.subject.meshImmune System Diseases
dc.subject.meshInterferon-beta
dc.subject.meshAntiviral Agents
dc.subject.meshSignal Transduction
dc.subject.meshCell Proliferation
dc.titleAntiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number9

Files

Original bundle

Now showing 1 - 2 of 2
No Thumbnail Available
Name:
PMC7230527.pdf
Size:
3.99 MB
Format:
Adobe Portable Document Format
No Thumbnail Available
Name:
Hurtado-Guerrero_Antiviral_MaterialSuplementario.pdf
Size:
569.69 KB
Format:
Adobe Portable Document Format